Early Development of an Innovative Nanoparticle-Based Multimodal Tool for Targeted Drug Delivery: A Step-by-Step Approach
Cells · 2025
DOI: 10.3390/cells14090670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Chiara Barattini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomolecular Sciences (DISB), University of Urbino Carlo Bo, 61029 Urbino, Italy. Hauptthemen laut MEDLINE: Nanoparticles, Drug Delivery Systems, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PhD course in Biomolecular and health sciences, University of Urbino.
Abstract (Originalsprache)
Prostate cancer is the most common tumor in men in developed countries and it often responds poorly to conventional treatments. Monoclonal antibody (MoAb) therapy, for this pathology, has grown tremendously in the past decades, exploiting naked and conjugated antibodies to cytotoxic payloads to form antibody drug conjugates (ADCs). Several studies have been carried out conjugating biomolecules against prostate-specific membrane antigen (PSMA), highly expressed in this tumor, to cytotoxic drugs. Nano-based formulations show high potential in targeted drug delivery to enhance the bioavailability of drugs. Our research aimed to evaluate the feasibility of setting up a nanoparticle-based multimodal tool for targeted drug delivery, describing the step-by-step approach and to perform a first screening of these fluorescent PEGylated silica nanoparticles employed in selective cancer cell targeting and killing. These nanoparticles featured a core–shell structure to contemporarily conjugate the antibody and the cytotoxic payload monomethyl auristatin E (MMAE) using a step-by-step approach. We compared the cytotoxic effect of this multimodal nanotool near the antibody-MMAE and free MMAE. We found a lower cytotoxicity effect of the nanoparticle-based construct compared to free drugs, likely because of the preservation of the previously observed receptor-mediated endocytosis. Nanomedicine is confirmed as a powerful alternative to organic drug delivery systems, even if some aspects, such as drug loading efficacy, release, scalable manufacturing and long-term stability, need to be deepened.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomolecular Sciences (DISB), University of Urbino Carlo Bo, 61029 Urbino, Italy.
- AcZon srl, 40050 Bologna, Italy.
- Department of Pure and Applied Sciences (DiSPeA), University of Urbino Carlo Bo, 61029 Urbino, Italy.
ORCID-Profile: Chiara Barattini, Daniele Lopez, Alfredo Ventola, Stefano Papa, Mariele Montanari, Barbara Canonico
Förderung
- PhD course in Biomolecular and health sciences
- University of Urbino
Zitieren
APA
Barattini, C., Volpe, A., Gori, D., Lopez, D., Ventola, A., Papa, S., Montanari, M., & Canonico, B. (2025). Early Development of an Innovative Nanoparticle-Based Multimodal Tool for Targeted Drug Delivery: A Step-by-Step Approach. Cells. https://doi.org/10.3390/cells14090670
Vancouver
Barattini C, Volpe A, Gori D, Lopez D, Ventola A, Papa S, et al. Early Development of an Innovative Nanoparticle-Based Multimodal Tool for Targeted Drug Delivery: A Step-by-Step Approach. Cells. 2025. doi:10.3390/cells14090670
BibTeX
@article{Barattini2025,
author = {Barattini, Chiara and Volpe, Angela and Gori, Daniele and Lopez, Daniele and Ventola, Alfredo and Papa, Stefano and Montanari, Mariele and Canonico, Barbara},
title = {Early Development of an Innovative Nanoparticle-Based Multimodal Tool for Targeted Drug Delivery: A Step-by-Step Approach},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14090670}
}
EUVIMED